Baker Avenue Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-68
| Closed | -$7.65K | – | 1063 |
|
|
2023
Q3 | $7.65K | Buy |
68
+55
| +423% | +$6.19K | ﹤0.01% | 823 |
|
|
2023
Q2 | $1.23K | Sell |
13
-3
| -19% | -$283 | ﹤0.01% | 1104 |
|
|
2023
Q1 | $1.62K | Sell |
16
-15
| -48% | -$1.52K | ﹤0.01% | 1032 |
|
|
2022
Q4 | $3.7K | Buy |
+31
| New | +$3.7K | ﹤0.01% | 849 |
|
|
2014
Q3 | – | Sell |
-17,980
| Closed | -$267K | – | 296 |
|
|
2014
Q2 | $267K | Buy |
+17,980
| New | +$267K | 0.04% | 238 |
|
|
2014
Q1 | – | Sell |
-16,500
| Closed | -$154K | – | 244 |
|
|
2013
Q4 | $154K | Buy |
16,500
+3,500
| +27% | +$32.7K | 0.03% | 244 |
|
|
2013
Q3 | $147K | Buy |
+13,000
| New | +$147K | 0.03% | 213 |
|